Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in IBD
Clinical Gastroenterology and Hepatology · 2026-05 · 24 (5) · 1472-1473
DOI: 10.1016/j.cgh.2025.06.031 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Cong Dai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China.
Zitieren
APA
Dai, C., Huang, Y. H., & Jiang, M. (2026). Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in IBD. Clinical Gastroenterology and Hepatology, 24(5), 1472-1473. https://doi.org/10.1016/j.cgh.2025.06.031
Vancouver
Dai C, Huang YH, Jiang M. Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in IBD. Clinical Gastroenterology and Hepatology. 2026;24(5):1472-1473. doi:10.1016/j.cgh.2025.06.031
BibTeX
@article{Dai2026,
author = {Dai, Cong and Huang, Yu-Hong and Jiang, Min},
title = {Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in IBD},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {5},
pages = {1472--1473},
doi = {10.1016/j.cgh.2025.06.031}
}
EUVIMED